FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110186.547	APPLICATION NO. 09/589,870
FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Stephen C. Goshorn et al.	
		FILING DATE June 5, 2000	GROUP ART UNIT 1642

Stamp: OIPE / MAR 2 9 2005 / PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	AJ					
	AK					
	AL					
	AM					
	AN					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

SR	AO	Dillman, R.O., "Monoclonal Antibody Therapy for Lymphoma," *Cancer Practice* 9(2): 71-80, March/April 2001.
	AP	Schultz, J. et al., "A Tetravalent Single-chain Antibody-Streptavidin Fusion Protein for Pretargeted Lymphoma Therapy," *Cancer Research 60*: 6663-6669, December 1, 2000.
	AQ	Zhang, M. et al., "Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213," *Blood 100*(1): 208-216, July 1, 2002.
	AR	Zhang, M. et al., "Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts," *Proc. Natl. Acad. Sci. 100*(4): 1891-1895, February 18, 2003.

EXAMINER	DATE CONSIDERED 6/6/08

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

1531647